プロパフェノン
±-プロパフェノン · 1-[2-[2-ヒドロキシ-3-(プロピルアミノ)プロポキシ]フェニル]-3-フェニル-1-プロパノン · 1-[2-[[2-ヒドロキシ-3-(プロピルアミノ)プロピル]オキシ]フェニル]-3-フェニル-1-プロパノン · 2'-[2-ヒドロキシ-3-(プロピルアミノ)プロポキシ]-α,β-ジヒドロカルコン · 2'-[2-ヒドロキシ-3-(プロピルアミノ)プロポキシ]-β-フェニルプロピオフェノン · プロパフェノン · rac-1-[2-[(2R*)-2-ヒドロキシ-3-(プロピルアミノ)プロポキシ]フェニル]-3-フェニル-1-プロパノン · ω-フェニル-2'-[2-ヒドロキシ-3-(プロピルアミノ)プロポキシ]プロピオフェノン
識別子と物理属性
| CAS No. | 54063-53-5 |
|---|---|
| 分子式 | C21H27NO3 |
| 平均分子量 | 341.4 g/mol |
| 単同位体質量 | 341.19909372 g/mol |
| SMILES | CCCNCC(O)COc1ccccc1C(=O)CCc1ccccc1 |
| InChIKey | JWHAUXFOSRPERK-UHFFFAOYSA-N |
| PubChem CID | 4932 |
| ChEMBL | CHEMBL631 |
| ChEBI | CHEBI:63619 |
| EC No. | 258-955-6 |
| DTXSID | DTXSID9045184 |
| 現地名 | プロパフェノン |
化学・物理的性質
| XLogP | 3.3 |
|---|---|
| 極性表面積 | 58.6 |
| 水素結合供与体数 | 2 |
| 水素結合受容体数 | 4 |
| 回転可能結合数 | 11 |
| 重原子数 | 25 |
| 形式電荷 | 0 |
| 複雑度 | 368 |
| 医薬品 | Pharmaceuticals -> Used in Switzerland |
| LogP（分配係数） | 3.23.83 |
| 溶解度 | Slightly soluble7.58e-03 g/LDMSO: 68 mg/mL (199.16 mM)Ethanol: 41 mg/mL (120.08 mM)759.9ug/L(22.5℃) |
| Human Drugs | Breast FeedingLactationMilk, HumanAntiarrhythmicsPharmaceuticals |
| Decomposition | When heated to decomposition, material emits toxic fumes of NOx and HCl. |
| Physical Description | Solid |
| Dissociation Constants | 9.278.8 |
| Collision Cross Section | 176.48 Ų [M+H]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]178.5 Ų [M+H]+ [CCS Type: TWMethod: Major Mix IMS/Tof Calibration Kit (Waters)] |
| Other Experimental Properties | MW: 377.90. Fine white crystalsslightly bitter taste. Soluble in basic lower aliphatic alcohols, carbon tetrachloride, hot waterslightly soluble in cold water. Insoluble in ether /Propafenone hydrochloride/ |
| 沸点 | 519.6±50.0 °C(Predicted) |
| 密度 | 1.096±0.06 g/cm3(Predicted) |
| 貯蔵条件 | 2-8°C |
| 外観・状態 | Solid |
| pKa（酸解離定数） | pKa 9.27 (Uncertain) |
| 色 | White to Off-White |
| 化粧品成分の機能 | 肌を保護する |
| CAS データベース | 54063-53-5(CAS DataBase Reference) |
| NISTの化学物質情報 | Propafenone(54063-53-5) |
安全性と法規制
| GHS 分類 | WarningH302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 2 reports by companies from 1 notifications to the ECHA C&L Inventory. |
|---|---|
| 規制情報 | REACH registered substance: Propafenone (EC: 258-955-6) |
| 火災の可能性 | This material is assumed to be combustible. |
| FDA 要件 | The Approved Drug Products with Therapeutic Equivalence Evaluations identifies currently marketed prescription drug products, including propafenone hydrochloride, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act. /Propafenone hydrochloride/ |
| Toxic Combustion Products | Emits toxic fumes under fire conditions. |
| Hazard Classes and Categories | Acute Tox. 4 (100%) |
| 消火手順 | Water spray, dry chemical, carbon dioxide, or foam as appropriate for surrounding fire and materials. ... As with all fires, evacuate personnel to a safe area. Firefighters should use self-contained breathing equipment and protective clothing. |
| 保管条件 | Store in tight, light-resistant container as defined in the USP-NF. This material should be handled and stored per label instructions to ensure product integrity.Commercially available propafenone hydrochloride immediate-release tablets and extended-release capsules should be stored in tight containers at a controlled room temperature of 25 °C, but may be exposed to temperatures ranging from 15-30 °C. Propafenone hydrochloride immediate-release tablets should be stored in light-resistant containers. When stored under such conditions, the commercially available immediate-release tablets have an expiration date of 3 years following the date of manufacture. |
| 清掃方法 | Wear approved respiratory protection, chemically compatible gloves, and protective clothing. Wipe up spillage or collect spillage using a high- efficiency vacuum cleaner. Avoid breathing dust. Place spillage in appropriately labeled container for disposal. Wash spill site. |
| 処分方法 | SRP: Expired or waste pharmaceuticals shall carefully take into consideration applicable DEA, EPA, and FDA regulations. It is not appropriate to dispose by flushing the pharmaceutical down the toilet or discarding to trash. If possible return the pharmaceutical to the manufacturer for proper disposal being careful to properly label and securely package the material. Alternatively, the waste pharmaceutical shall be labeled, securely packaged and transported by a state licensed medical waste contractor to dispose by burial in a licensed hazardous or toxic waste landfill or incinerator. |
用途
用途
ナトリウムチャネル抑制薬（Ⅰc群）抗不整脈薬
使用
Cardiac depressant (anti-arrhythmic).
一般的な説明
Propafenone, 2-[2＇-hydroxy-3-(propylamino)propoxy]-3-phenylpropiophenone (Rythmol), a classIC antiarrhythmic drug, contains a chiral center and is marketedas the racemic mixture. Therapy with the racemicmixture of propafenone produces effects that can be attributedto both (S) and (R) enantiomers. Although (R) and (S)enantiomers exert similarNa+channel–blocking effects, the(S) enantiomer also produces aβ-adrenergic blockade. As aresult, the (S) enantiomer is reported to be 40-fold morepotent than the (R) enantiomer as an antiarrhythmic agent.The enantiomers also display stereoselective dispositioncharacteristics. The (R) enantiomer is cleared more quickly.Hepatic metabolism is polymorphic and determined genetically.Ten percent of Caucasians have a reduced capacity tohydroxylate the drug to form 5-hydroxypropafenone. Thispolymorphic metabolism accounts for the interindividualvariability in the relationships between dose and concentrationand, thus, variability in the pharmacodynamic effects ofthe drug. The 5-hydroxy metabolites of both enantiomersare as potent as the parent compound in blocking Na+channels.Propafenone also depresses the slow inward current ofCa2+ions.